Nityr and Primidone
Determining the interaction of Nityr and Primidone and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9, such as warfarin and phenytoin. The proposed mechanism is decreased clearance due to nitisinone-mediated inhibition of CYP450 2C9 isoenzyme. MANAGEMENT: Caution is advised if nitisinone is used concomitantly with drugs that are substrates of CYP450 2C9, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever nitisinone is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects. References "Product Information. Orfadin (nitisinone)." Orphan Pharmaceuticals USA, Inc, Nashville, TN. Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink." Cerner Multum, Inc. "Australian Product Information." O 0
Professional:MONITOR: Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9, such as warfarin and phenytoin. The proposed mechanism is decreased clearance due to nitisinone-mediated inhibition of CYP450 2C9 isoenzyme.
MANAGEMENT: Caution is advised if nitisinone is used concomitantly with drugs that are substrates of CYP450 2C9, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever nitisinone is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.
- "Product Information. Orfadin (nitisinone)." Orphan Pharmaceuticals USA, Inc, Nashville, TN.
- Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
- Cerner Multum, Inc. "Australian Product Information." O 0
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.